Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
Clinical trial NCT04642469 · COMPLETED
Trial details
- NCT number
- NCT04642469
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-30
- Primary completion
- 2023-05-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.